Related Experiment Video
Updated: Jan 4, 2026
03:23
Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis
Published on: May 10, 2024
1.3K
Emerging therapies for eosinophilic esophagitis.
Thomas Greuter1, Ikuo Hirano2, Evan S Dellon3
1Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.
The Journal of Allergy and Clinical Immunology
|November 10, 2019
Summary
Eosinophilic esophagitis (EoE) treatment is advancing with new topical steroids, biologics, and dietary strategies. Future therapies may target novel molecular mediators for improved patient outcomes.
Area of Science:
- Gastroenterology
- Immunology
- Allergy
Background:
- Eosinophilic esophagitis (EoE) lacks FDA-approved targeted therapies.
- Current off-label treatments include topical corticosteroids, dietary changes, and dilation.
- Understanding EoE pathogenesis is crucial for developing new treatments.
Purpose of the Study:
- To review recent advancements in EoE treatment strategies.
- To discuss the role of novel therapeutic agents and approaches.
- To highlight potential future therapeutic targets for EoE.
Main Methods:
- Review of recent clinical trials and research in EoE treatment.
- Analysis of new drug formulations, biologic agents, and dietary interventions.
- Exploration of emerging molecular targets based on EoE pathogenesis.
Main Results:
- Development of new topical steroid formulations, including an approved budesonide effervescent tablet in Europe.
- Phase II trials investigating biologics for EoE, drawing from treatments for other TH2-mediated diseases.
- Evolution of novel dietary restriction strategies for managing EoE.
Conclusions:
- Significant progress is being made in EoE treatment options.
- New topical steroids, biologics, and dietary approaches offer improved management.
- Further research into molecular targets holds promise for future EoE therapies.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
01:21Barrett Esophagus-II: Clinical Manifestations and Management
712
Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
712
01:19Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K
01:29Gastroesophageal Reflux Disease II: Clinical Features and Management
638
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
638
01:26Peptic Ulcer Disease IV: Management
389
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
389
01:17Drugs for Treatment of Diarrhea-Predominant IBS
580
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
580